CERO THERAPEUTICS HOLDINGS, INC. (CERO): debt financing — CERo Therapeutics issues $500K convertible note to Keystone Capital at 10% interest

CERO THERAPEUTICS HOLDINGS, INC.

Initial purchase price $400,000; principal face value $500,000; up to $1M aggregate available.
Note matures April 27, 2027; bears 10% annual interest; convertible at lower of $0.05 or 80% of 5 lowest intraday prices in prior 20 days.
Conversion subject to 4.99% beneficial ownership limitation; resale registration required on Form S-1 or S-3.
Issuance exempt under Section 4(a)(2) and Rule 506(b); accredited investor only.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $400,000, having a principal face value of $500,000 with Keystone Capital Partners, LLC at 10% per annum maturing April 27, 2027.

Instrument: convertible notes
Principal: $400,000, having a principal face value of $500,000
Counterparty: Keystone Capital Partners, LLC
Rate: 10% per annum
Maturity: April 27, 2027
Event: incurrence

Exact text from the filing

On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the "Company") issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the "Note") to Keystone Capital Partners, LLC ("Lender").

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for $400,000.

Security: convertible note
Purchaser: Keystone Capital Partners, LLC
Consideration: $400,000

Exact text from the filing

On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. entered into Note with Keystone Capital Partners, LLC valued at $400,000 (effective 2026-04-27).

Action: entry
Agreement: notes offering
Counterparty: Keystone Capital Partners, LLC
Value: $400,000
Effective: 2026-04-27

Exact text from the filing

On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-050951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.